NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

557.85 -12.15 (-2.13%)

27.86% Fall from 52W High

309.9K NSE+BSE Volume

NSE 26 Sep, 2025 3:58 PM (IST)

24,350.2

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

01 Aug 2018

557.85

-2.13%

Emami's revenue grew by 19%, 4% below our estimate, led by a weak performance of Kesh Kin...

Accumulate: Emami Ltd.

Emkay

Emami's revenue grew by 19%, 4% below our estimate, led by a weak performance of Kesh King, Male Grooming and International business. EBITDA grew by 54%, in line with our estimate due to margin expansion while Adjusted PAT of Rs704mn was 9% below...

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

18 Jun 2018

557.85

-2.13%

Emami Ltd. (@ CMP of 1098)

Neutral: Emami Ltd.

Edelweiss

Emami is a leading FMCG player in India, operating in certain attractive segments such as skin care and hair oil. The company is promoted by Kolkatabased...

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

04 May 2018

557.85

-2.13%

Emami (4QFY18): Awaiting for recovery. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We value Emami based on P/E of 36x on Mar-20 EPS to arrive at a TP of Rs 1,230. We maintain BUY. Emamis consolidated revenues grew by 12% on a like-like basis (in-line) driven by 9% volume growth. We were surprised with EBITDA/APAT decline of -3/-5% vs. expectation of 9/3% respectively.

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

31 Jan 2018

557.85

-2.13%

Emami Ltd Q3FY18 results comment

Results Update: Emami Ltd.

HDFC Securities

Emami Ltd Q3FY18 results comment Revenue rose by 20.46% to Rs. 756.64 Cr in Q3FY18 when compared to the previous quarter

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

30 Jan 2018

557.85

-2.13%

Emami (3QFY18): Pain relief specialist? Yes. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We maintain BUY. Emami disappointed us on revenue growth and EBITDA margins. Net revenue was up 6% at Rs 7.6bn. Like-to-like revenue growth was slow at 10% (6% volume growth) vs. expectation of 17%. Kesh King and Health Supplements revenue contracted by 19% and 2%, impacting domestic performance. International posted healthy 16% growth, led by favorable base. EBITDA and APAT were up 2% and 4% respectively.

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

30 Jan 2018

557.85

-2.13%

Emami - 3QFY18 Result Update

Buy: Emami Ltd.

Reliance Securities

Despite lower base in 3QFY17 owing to demonetisation, Emami has reported a disappointed set of numbers for 3QFY18. While its consolidated net sales grew by 6% YoY to Rs7.6bn (vs. our estimate of Rs8.1bn), net profit came in at Rs1.5bn, lower than our estimate of Rs1.6bn....

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

09 Jan 2018

557.85

-2.13%

Emami: Rural recovery just the beginning of growth revival

Buy: Emami Ltd.

Motilal Oswal

It is a great play on rural demand growth and wholesale recovery. Before the slowdown caused by extraordinary factors like demonetization, Emami had the best track record among peers on consistency of earnings growth, which we expect will make a comeback. Emami has a formidable portfolio of dominant brands, with best-in-class R&D and advertisement to support existing brands and new launches. Despite likely resumption of better-than-peers' earnings growth of 20% CAGR over FY18-21, the stock trades in line with peer multiples. Our target price of INR1655 implies a one-year upside of 23% and a two-year upside of 39%. Our bull case upside is 33% for one year and 53% for two years.

Emami Ltd. has an average target of 763.29 from 7 brokers.

Emami Ltd.

27 Oct 2017

557.85

-2.13%

Master Pick- Emami Limited

Buy: Emami Ltd.

Recommendation Target

Religare

Emami Ltd is one of the leading and fastest growing personal and healthcare businesses in India, with an enviable portfolio of household brand names such as Boroplus, Navratna, Fair and Handsome, Zandu balm, Mentho Plus balm and Fast Relief. Emami has received countless accolades for its innovative and clutter-breaking products, which have carved out whole new segments from scratch in the Indian FMCG space .

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Is Emami Ltd. worth buying?

225 Votes:

Buy 74.67%

Sell 17.33%

Hold 8.0%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf